Darling Ingredients and its health brand Rousselot today announced that the U.S. Patent and Trademark Office (USPTO) has granted Patent No. US12636339 for Nextida GC, a first-of-its-kind collagen peptide ingredient developed to help support healthy after-meal blood sugar levels, naturally. The patent protects both the production process and the use of Nextida GC as a dietary supplement ingredient, offering a non-pharmaceutical option for managing blood glucose through science-backed nutrition.
“This patent reinforces the scientific foundation behind Nextida GC and highlights Darling Ingredients’ ability to translate its collagen expertise into targeted health solutions,” said Randall C. Stuewe, Chairman and Chief Executive Officer. “As demand grows for natural, non-pharmaceutical approaches to health and wellness, we are strengthening our leadership in collagen peptide health ingredients while building a broader pipeline of Nextida solutions.”
Nextida GC is a collagen peptide composition formulated for dietary supplement applications related to natural glucose control and metabolic support. It is part of an expanding portfolio of collagen products being developed to address distinct functional health needs.
Australia (AU2023279850B2), Europe (EP4498839B1), Japan (JP7751755B2) and China (CN119212574B) have also awarded patents for Nextida GC, with additional patents pending in Brazil, Canada, Colombia, Korea, Mexico, India and Peru.
For more information about Nextida GC and Rousselot’s portfolio of science-backed collagen solutions, visit rousselot.com.